Information Provided By: 
Fly News Breaks for February 21, 2019
BTX
Feb 21, 2019 | 07:07 EDT
H.C. Wainwright analyst Joseph Pantginis started BioTime with a Buy rating and $4 price target. The company has returned its to its roots with a singular focus on cellular therapy for unmet medical needs and has become more deliberate in its strategic decisions for its platform assets, Pantginis tells investors in a research note. He believes believe BioTime is in a "position of strength with regard to its multiple business development options going forward."
News For BTX From the Last 2 Days
There are no results for your query BTX
